vs
艾伯维（ARGX）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
艾伯维自由现金流更多（$322.4M vs $-139.5M）
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
ARGX vs RVMD — 直观对比
营收规模更大
ARGX
是对方的Infinity倍
$0
自由现金流更多
ARGX
多$461.9M
$-139.5M
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $0 |
| 净利润 | $877.2M | $-194.6M |
| 毛利率 | 89.5% | — |
| 营业利润率 | 28.9% | — |
| 净利率 | 35.5% | — |
| 营收同比 | 83.2% | — |
| 净利润同比 | 1.3% | -20.4% |
| 每股收益（稀释后） | $13.25 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARGXRVMD
| Q4 25 | $2.5B | — | ||
| Q2 25 | $1.8B | — | ||
| Q4 24 | $1.4B | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $901.9M | $0 | ||
| Q1 24 | — | $0 | ||
| Q4 23 | — | $742.0K | ||
| Q3 23 | — | $0 |
净利润ARGXRVMD
| Q4 25 | $877.2M | — | ||
| Q2 25 | $414.8M | — | ||
| Q4 24 | $865.6M | $-194.6M | ||
| Q3 24 | — | $-156.3M | ||
| Q2 24 | $-32.5M | $-133.2M | ||
| Q1 24 | — | $-116.0M | ||
| Q4 23 | — | $-161.5M | ||
| Q3 23 | — | $-108.4M |
毛利率ARGXRVMD
| Q4 25 | 89.5% | — | ||
| Q2 25 | 89.2% | — | ||
| Q4 24 | 90.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 89.4% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
营业利润率ARGXRVMD
| Q4 25 | 28.9% | — | ||
| Q2 25 | 19.2% | — | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -15.4% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -24256.5% | ||
| Q3 23 | — | — |
净利率ARGXRVMD
| Q4 25 | 35.5% | — | ||
| Q2 25 | 23.4% | — | ||
| Q4 24 | 64.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -21770.5% | ||
| Q3 23 | — | — |
每股收益（稀释后）ARGXRVMD
| Q4 25 | $13.25 | — | ||
| Q2 25 | $6.32 | — | ||
| Q4 24 | $13.33 | $-1.13 | ||
| Q3 24 | — | $-0.94 | ||
| Q2 24 | $-0.55 | $-0.81 | ||
| Q1 24 | — | $-0.70 | ||
| Q4 23 | — | $-1.23 | ||
| Q3 23 | — | $-0.99 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5B | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $2.3B |
| 总资产 | $8.7B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARGXRVMD
| Q4 25 | $3.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q4 24 | $1.5B | $2.3B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $1.4B | $1.6B | ||
| Q1 24 | — | $1.7B | ||
| Q4 23 | — | $1.9B | ||
| Q3 23 | — | $813.2M |
总债务ARGXRVMD
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $11.0M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
股东权益ARGXRVMD
| Q4 25 | $7.3B | — | ||
| Q2 25 | $6.1B | — | ||
| Q4 24 | $5.5B | $2.3B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | $4.3B | $1.6B | ||
| Q1 24 | — | $1.7B | ||
| Q4 23 | — | $1.8B | ||
| Q3 23 | — | $837.5M |
总资产ARGXRVMD
| Q4 25 | $8.7B | — | ||
| Q2 25 | $7.2B | — | ||
| Q4 24 | $6.2B | $2.6B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | $4.8B | $1.8B | ||
| Q1 24 | — | $1.9B | ||
| Q4 23 | — | $2.1B | ||
| Q3 23 | — | $984.2M |
负债/权益比ARGXRVMD
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $323.3M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $322.4M | $-139.5M |
| 自由现金流率自由现金流/营收 | 13.0% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.37× | — |
| 过去12个月自由现金流最近4个季度 | $594.5M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流ARGXRVMD
| Q4 25 | $323.3M | — | ||
| Q2 25 | $361.8M | — | ||
| Q4 24 | $41.9M | $-138.3M | ||
| Q3 24 | — | $-130.4M | ||
| Q2 24 | $-124.7M | $-128.2M | ||
| Q1 24 | — | $-160.6M | ||
| Q4 23 | — | $-120.6M | ||
| Q3 23 | — | $-100.5M |
自由现金流ARGXRVMD
| Q4 25 | $322.4M | — | ||
| Q2 25 | $356.6M | — | ||
| Q4 24 | $40.9M | $-139.5M | ||
| Q3 24 | — | $-133.9M | ||
| Q2 24 | $-125.5M | $-130.6M | ||
| Q1 24 | — | $-163.7M | ||
| Q4 23 | — | $-122.9M | ||
| Q3 23 | — | $-103.0M |
自由现金流率ARGXRVMD
| Q4 25 | 13.0% | — | ||
| Q2 25 | 20.1% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.9% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -16560.6% | ||
| Q3 23 | — | — |
资本支出强度ARGXRVMD
| Q4 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 312.3% | ||
| Q3 23 | — | — |
现金转化率ARGXRVMD
| Q4 25 | 0.37× | — | ||
| Q2 25 | 0.87× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
